Filtered By:
Source: International Journal of Cardiology
Condition: Cardiomyopathy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 31 results found since Jan 2013.
Risk of cardioembolic ischemic events and relation to atrial fibrillation/flutter in patients with arrhythmogenic cardiomyopathy during a long-term follow-up
This study sought to determine the occurrence of cardioembolic ischemic events (CIEs) in ACM patients and to identify clinical and imaging predictors of CIEs.
Source: International Journal of Cardiology - July 21, 2023 Category: Cardiology Authors: Elisabetta Toso, Francesca De Lio, Pier Paolo Bocchino, Claudia Raineri, Francesco Fioravanti, Elena Maria Richiardi, Gianluca Marcelli, Tania Sacco, Carla Giustetto, Fiorenzo Gaita Source Type: research
Surgical ablation in hypertrophic obstructive cardiomyopathy: What is the real deal?
Atrial fibrillation (AF) is the most common tachyarrhythmia in patients with hypertrophic obstructive cardiomyopathy (HOCM), with an estimated prevalence of approximately 20% [1]. AF is associated with malignant outcomes in patients with HOCM, with an increased risk of embolic stroke, heart failure, severe functional impairment and mortality [2]. Furthermore, AF is poorly tolerated by patients with HOCM, with increased heart failure episodes, hemodynamic instability and impaired quality of life [3].
Source: International Journal of Cardiology - July 8, 2023 Category: Cardiology Authors: Alessandra Sala, Ottavio Alfieri Tags: Editorial Source Type: research
The real world of stroke incidence in patients with hypertrophic cardiomyopathy
We have read a paper with great interest written by Fumagalli and colleagues concerning “the incidence of stroke in patients with hypertrophic cardiomyopathy (HCM) among different heart rhythm” [1]. In this paper, the authors found that stroke rates in HCM patients no prior history of atrial fibrillation (AF), stroke rates were similar in those with de novo AF or stable sinus rate (SR). And they further observed that severe left atrium dilatation was a powerful risk factor, irrespective of AF. The results provided evidence for the anticoagulation strategies to prevent stroke in patients with HCM.
Source: International Journal of Cardiology - July 7, 2023 Category: Cardiology Authors: Xinru Chen Tags: Letter to the Editor Source Type: research
Stroke in hypertrophic cardiomyopathy. Never mind the rhythm
“Il core à quattro ventriculi, cioè due inferiori e nella sustanza del core e due superiori for della sustanza del core, … e li superiori son separati da certi uscioli (ovver porte del core) dalli ventricoli inferiori”.“The heart has four ventricles, that is two lower in the substance of t he heart, and two upper outside the substance of the heart, ... and the upper ones are separated by little doors from the lower ventricles”.Leonardo da Vinci, The Royal collection, Windsor, UK.
Source: International Journal of Cardiology - May 25, 2023 Category: Cardiology Authors: Maurizio Pieroni, Michele Ciabatti, Leonardo Bolognese Tags: Editorial Source Type: research
Incidence of stroke in patients with hypertrophic cardiomyopathy in stable sinus rhythm during long-term monitoring
Patients with hypertrophic cardiomyopathy (HCM) are at increased risk of stroke, but the incidence and factors associated with cardioembolic events in HCM patients without atrial fibrillation (AF) remain unresolved. We determined the incidence of stroke in patients in sinus rhythm (SR) monitored with a cardiac implantable electronic device (CIED).
Source: International Journal of Cardiology - April 13, 2023 Category: Cardiology Authors: Carlo Fumagalli, Francesca Bonanni, Matteo Beltrami, Roberta Ruggieri, Chiara Zocchi, Luigi Tassetti, Niccol ò Maurizi, Martina Berteotti, Mattia Zampieri, Alessia Argirò, Fabrizio Lovero, Alessia Tomberli, Mauro di Bari, Niccolò Marchionni, Paolo Pier Source Type: research
The hospitalizations in hypertrophic cardiomyopathy: “the dark side of the moon”.
Hypertrophic cardiomyopathy (HCM) is a myocardial disease characterized by left ventricular hypertrophy not solely explainable by abnormal loading condition [1,2]. Patients with HCM show a different clinical course, ranging from an asymptomatic status, with no adverse events and normal or extended longevity, to a symptomatic condition in which several disease complications can occur [3]. Among HCM patients which experience disease progression, 3 different pathways have been identified: refractory heart failure (HF), requiring surgical myectomy/alcohol ablation (obstructive HCM, OHCM) or heart transplant (non-obstructive HC...
Source: International Journal of Cardiology - August 14, 2020 Category: Cardiology Authors: Emanuele Monda, Giuseppe Limongelli Tags: Editorial Source Type: research
The hospitalizations in hypertrophic cardiomyopathy: “The dark side of the moon”
Hypertrophic cardiomyopathy (HCM) is a myocardial disease characterized by left ventricular hypertrophy not solely explainable by abnormal loading condition [1,2]. Patients with HCM show a different clinical course, ranging from an asymptomatic status, with no adverse events and normal or extended longevity, to a symptomatic condition in which several disease complications can occur [3]. Among HCM patients which experience disease progression, 3 different pathways have been identified: refractory heart failure (HF), requiring surgical myectomy/alcohol ablation (obstructive HCM, OHCM) or heart transplant (non-obstructive HC...
Source: International Journal of Cardiology - August 14, 2020 Category: Cardiology Authors: Emanuele Monda, Giuseppe Limongelli Tags: Editorial Source Type: research
Clinical profile and outcome of cardiac involvement in MELAS syndrome
We describe the clinical profile, outcome and clinical implication of MELAS-associated cardiomyopathy at a tertiary referral centre.
Source: International Journal of Cardiology - October 23, 2018 Category: Cardiology Authors: Alice Brambilla, Silvia Favilli, Iacopo Olivotto, Giovanni Battista Calabri, Giulio Porcedda, Luciano De Simone, Elena Procopio, Elisabetta Pasquini, Maria Alice Donati Source Type: research
Temporal trends of the prevalence and incidence of atrial fibrillation and stroke among Asian patients with hypertrophic cardiomyopathy: A nationwide population-based study
Atrial fibrillation (AF) and stroke are common in hypertrophic cardiomyopathy (HCM). We aimed to determine the prevalence and incidence of AF and stroke in patients with HCM during a 10-year period.
Source: International Journal of Cardiology - August 10, 2018 Category: Cardiology Authors: You-Jung Choi, Eue-Keun Choi, Kyung-Do Han, Jin-Hyung Jung, Jiesuck Park, Euijae Lee, Wonseok Choe, So-Ryoung Lee, Myung-Jin Cha, Woo-Hyun Lim, Seil Oh Source Type: research
Could direct oral anticoagulants be an alternative to vitamin K antagonists in patients with hypertrophic cardiomyopathy and atrial fibrillation?
We read the article “Direct oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation” by Fernando Dominguez et al. [1] interestingly, which has great clinical significance in guiding the use of oral anticoagulants in patients with hypertrophic cardiomyopathy (HCM) and atrial fibrilla tion (AF). Due to the high risk of stroke and thromboembolic complications in patients with HCM and AF, vitamin K antagonists (VKAs) are recommended for those patients, direct oral anticoagulants (NOACs) may represent another option [2].
Source: International Journal of Cardiology - February 15, 2018 Category: Cardiology Authors: Biao Li, Chao Sun, Fen Qin, Na Liu, Zhihong Wu, Qiming Liu Tags: Letter to the Editor Source Type: research
The impact of migration on cardiovascular diseases
Cardiovascular disease (CVD) is now the leading contributor to disability-adjusted life years lost worldwide [1]. Within CVD, ischaemic heart disease and stroke rank first and second [1], with hypertensive heart disease and heart failure, rheumatic heart disease (RHD), cardiomyopathy and atrial fibrillation also contributing substantially [2]. There is clear international commitment to address this issue. The WHO 25 ×25 Global Action Plan [3], and the Sustainable Development Goals [4] set ambitious targets to reduce premature mortality from CVD.
Source: International Journal of Cardiology - January 29, 2018 Category: Cardiology Authors: Anna Odone, Charlotte McKee, Martin McKee Tags: Editorial Source Type: research
Telomere length: A newly marker for predicting atrial fibrillation?
We read with great interest a recent article published in your journal entitled “Telomere shortening and telomerase activity in ischaemic cardiomyopathy patients – Potential markers of ventricular arrhythmia”. This paper demonstrated that telomere length (TL) was associated with fatal ventricular arrhythmia without a causal relationship being reported [1]. Shortening in T L has been linked to an increase in the risks of cardioembolic stroke [2] and cardiovascular diseases [3]. Recently, the potential relationship between TL and with atrial fibrillation (AF) has been investigated with conflicting results.
Source: International Journal of Cardiology - May 29, 2017 Category: Cardiology Authors: Nixiao Zhang, Gary Tse, Xue Liang, Guangping Li, Tong Liu Tags: Letter to the Editor Source Type: research
Association of elevated pulmonary artery systolic pressure with stroke and systemic embolic events in patients with hypertrophic cardiomyopathy
This study aimed to determine whether elevated PASP is associated with stroke and systemic embolic events in a tertiary referral HCM cohort.
Source: International Journal of Cardiology - May 5, 2017 Category: Cardiology Authors: Keigo Kanbayashi, Yuichiro Minami, Shintaro Haruki, Ryozo Maeda, Ryosuke Itani, Kyomi Ashihara, Nobuhisa Hagiwara Tags: Short communication Source Type: research
Comparison of linear versus cubic assessment of left atrial size in the prediction of atrial fibrillation development in hypertrophic cardiomyopathy
Left atrial (LA) enlargement evaluated by echocardiography is a very strong predictor of cardiovascular (CV) outcomes such as atrial fibrillation (AF), stroke, congestive heart failure, and CV death in multiple clinical settings [1,2]. As a consequence, researchers have focused their attention on the best method to assess LA size. Left atrium is a thin-walled cardiac chamber directly exposed to left ventricular (LV) pressure during diastole, which represents its afterload. In particular, in hypertrophic cardiomyopathy (HCM), almost all patients have some degree of LV diastolic dysfunction.
Source: International Journal of Cardiology - March 16, 2016 Category: Cardiology Authors: Alessandra Giamundo, Grazia Canciello, Antonio Rapacciuolo, Francesca Musella, Gianluigi Savarese, Teresa Strisciuglio, Eugenio Stabile, Raffaele Izzo, Bruno Trimarco, Maria Angela Losi Source Type: research
Ventricular Tachycardia associated with Mid-Ventricular Obstructive Hypertrophic Cardiomyopathy and Apical Aneurysm
We report a case of a 68-years old man who came to the Emergency Department because of a Stroke preceded by episodes of fainting.
Source: International Journal of Cardiology - August 10, 2015 Category: Cardiology Authors: G. Cannavà, A. Currò Source Type: research
